Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Evidence from the peritoneal dialysis literature suggests that the peritoneal permeability of a number of hydrophilic anticancer drugs may be considerably less than plasma clearance. Pharmacokinetic calculations indicate that such drugs administered ip in large volumes are expected to maintain a significantly greater concentration in the peritoneal space than in the plasma. This concentration difference offers a potentially exploitable biochemical advantage in the treatment of patients with presumed microscopic residual ovarian cancer confined to the peritoneal cavity.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism; D001202:Ascitic Fluid / Q000378:metabolism; D003561:Cytarabine / Q000008:administration & dosage / Q000378:metabolism; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008727:Methotrexate / Q000008:administration & dosage / Q000378:metabolism; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014018:Tissue Distribution
D000970:Antineoplastic Agents; D003561:Cytarabine; D008727:Methotrexate